key: cord-1031836-41vfg8xr
authors: Schmidt, Tina; Klemis, Verena; Schub, David; Schneitler, Sophie; Reichert, Matthias C.; Wilkens, Heinrike; Sester, Urban; Sester, Martina; Mihm, Janine
title: Cellular immunity predominates over humoral immunity after homologous and heterologous mRNA and vector‐based COVID‐19 vaccine regimens in solid organ transplant recipients
date: 2021-09-06
journal: Am J Transplant
DOI: 10.1111/ajt.16818
sha: 8f2b02efaa5c2e9c960533f134c4001388393a21
doc_id: 1031836
cord_uid: 41vfg8xr

Knowledge on the immunogenicity of vector‐based and mRNA‐vaccines in solid organ transplant recipients is limited. Therefore, SARS‐CoV‐2–specific T cells and antibodies were analyzed in 40 transplant recipients and 70 controls after homologous or heterologous vaccine‐regimens. Plasmablasts and SARS‐CoV‐2–specific CD4 and CD8 T cells were quantified using flow cytometry. Specific antibodies were analyzed by ELISA and neutralization assay. The two vaccine types differed after the first vaccination, as IgG and neutralizing activity were more pronounced after mRNA priming (p = .0001 each), whereas CD4 and CD8 T cell levels were higher after vector priming (p = .009; p = .0001). All regimens were well tolerated, and SARS‐CoV‐2–specific antibodies and/or T cells after second vaccination were induced in 100% of controls and 70.6% of transplant recipients. Although antibody and T cell levels were lower in patients, heterologous vaccination led to the most pronounced induction of antibodies and CD4 T cells. Plasmablast numbers were significantly higher in controls and correlated with SARS‐CoV‐2–specific IgG‐ and T cell levels. While antibodies were only detected in 35.3% of patients, cellular immunity was more frequently found (64.7%) indicating that assessment of antibodies is insufficient to identify COVID‐19‐vaccine responders. In conclusion, heterologous vaccination seems promising in transplant recipients, and combined analysis of humoral and cellular immunity improves the identification of responders among immunocompromised individuals.

Currently authorized vaccines toward the severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) include mRNA vaccines and adenovirus-based replication-incompetent vector vaccines. Both vaccine types including the heterologous vector-mRNA combination have proved to be strongly immunogenic [1] [2] [3] [4] and highly efficient in preventing severe coronavirus disease in immunocompetent individuals. [1] [2] [3] Immunocompromised individuals such as patients after solid organ transplantation are at higher risk to suffer from more severe disease. 5 Therefore, COVID-19 vaccination is generally recommended for transplant recipients with no preference towards the use of either mRNA or vectorbased vaccines. 6, 7 It has become evident that humoral immunity in transplant recipients immunized with mRNA-based COVID -19 vaccines was only induced in approximately 6%-17% after the first dose, [8] [9] [10] and up to 59% after the second dose, [11] [12] [13] [14] [15] [16] respectively.

Risk factors for poor response included older age, more intense immunosuppressive drug regimens including depleting antibodies and anti-metabolites, and earlier time after transplantation. 8, 11 While the ability to induce antibodies has primarily been reported so far, knowledge on vaccine-induced cellular immunity in transplant recipients is limited and restricted to mRNA vaccines, 17, 18 whereas immunogenicity in transplant recipients after administration of vector-based vaccines is currently unknown, and general knowledge on potential differences of immunogenicity between the two vaccine types is scarce. Although both the mRNA vaccines and the currently licensed vector vaccine ChAdOx1 nCoV-19 are administered twice, the recommended time interval between the first and the second dose varies from 3-6 weeks for mRNA vaccines to 9-12 weeks for the ChAdOx1 nCoV-19 vaccine. 6 Here we report the results of a prospective study assessing the vaccine-induced humoral and cellular immune response in solid organ transplant recipients in comparison with a healthy agematched control group. The vector vaccine ChAdOx1 nCoV-19 and the mRNA vaccines BNT162b2 or mRNA-1273 including homologous and heterologous regimens were assigned as per national policies. 6, 7 To allow direct comparison of immunogenicity of the two vaccine types independent of the recommended time interval between the first and the second dose, we analyzed primary induction of humoral and cellular immunity after the first vaccine dose. In addition, immunogenicity and reactogenicity after a second homologous and heterologous dose was characterized to estimate the overall response after a complete vaccine regimen.

Solid organ transplant recipients and age-matched immunocompetent controls with no known history of SARS-CoV-2 infection were included in the study. Individuals either received homologous or heterologous regimens consisting of the adenovirus-vector vaccine ChAdOx1 nCoV-19 or mRNA-vaccines (BNT162b2 or mRNA-1273) as per national recommendation. 7 Lymphocyte subpopulations as well as vaccine-induced SARS-CoV-2-specific humoral and cellular immune responses were analyzed from heparinized whole blood 13-30 days after the first and the second vaccination (except for one healthy control tested 7 days after the second vaccination). Results after secondary vaccination of 32 controls were included as part of a previous study on 216 immunocompetent controls. 4 Analyses of lymphocyte subpopulations and antigen-specific T cells were carried out within 24 h.

Antibody testing was performed from frozen plasma samples.

Baseline levels of SARS-CoV-2-reactive antibodies were determined to control for pre-existing immunity. Antibodies toward the nucleocapsid protein were analyzed to estimate infection after vaccination. Local and systemic adverse events within 7 days after vaccinations were recorded using a questionnaire. The study was approved by the ethics committee of the Ärztekammer des Saarlandes (reference 76/20), and all individuals gave written informed consent.

on 100 µl heparinized whole blood exactly as described before 4, 19 using monoclonal antibodies towards CD3 (clone SK7), CD19 (clone HIB19), CD27 (clone L128), CD38 (clone HB7), and IgD (clone IA6-2). Cells were analyzed using flow cytometry (FACS-Canto-II or FACSLyric) and FACS-Diva-V6.1.3 or FlowJo software (BD Biosciences). Among total lymphocytes, T and B cells were identified by expression of CD3 and CD19, respectively.

Plasmablasts were gated as CD38 positive cells among IgD-CD27+ CD19 positive switched-memory B cells as described before. 4 Differential blood counts were used to calculate absolute lymphocyte numbers.

immunostained using anti-CD4 (clone SK3), anti-CD8 (clone SK1), anti-CD69 (clone L78), anti-IFNγ (clone 4S.B3), anti-IL-2 (clone MQ1-17H12), and anti-TNFα (clone MAb11). SARS-CoV-2-reactive CD4 or CD8 T cells were identified as activated CD69 positive T cells producing IFNγ using flow-cytometry based on a gating strategy as described before. 4 In addition, co-expression of IL-2 and TNFα was analyzed after Boolean gating to characterize functionality in more detail. Reactive CD4 and CD8 T cell levels after control stimulations were subtracted from levels obtained after SARS-CoV-2-specific stimulation, and 0.03% of reactive T cells was set as detection limit as described before 4 based on the distribution of T cell frequencies after control stimulations (97.5% of control stimulations below this threshold). 

Mann-Whitney and Kruskall-Wallis tests were performed to compare unpaired non-parametric data between groups. Paired analyses of T cell and antibody levels were performed using the Wilcoxon matched pairs test. Data with normal distribution were analyzed using unpaired t test. Categorial analyses were performed using Fisher's exact and Chi-square test as indicated. Correlations were analyzed according to Spearman. Statistical analysis was carried out using GraphPad Prism 9.0 software (GraphPad, San Diego, CA) using two-tailed tests. Multivariate analysis on vaccine response was performed using IBM-SPSS Statistics-26. A p-value < .05 was considered statistically significant.

Forty solid organ transplant recipients and 70 immunocompetent controls were recruited and tested at a median of 15 (IQR 6) days after the first vaccination with either vector or mRNA-vaccine, which was applied in 75% and 25% of individuals, respectively. Among vector-primed individuals, approximately two-thirds received heterologous boosting with mRNA. One patient refused the second dose, and one patient was lost to follow-up. Immunogenicity after secondary vaccination was analyzed at a median of 14 (IQR 1) days.

All individuals had no known history of SARS-CoV-2 infection. The two groups were matched regarding age, and vaccine combinations, but there were more males among patients (Table 1 ). Patients were transplanted for 6.5 (IQR 9.9) years, and the majority of patients (28/40, 70%) were on an immunosuppressive triple-drug regimen including a calcineurin inhibitor, glucocorticoids and an antimetabolite (Table 1) . Three patients were within one year after transplantation (8.5-11.8 months), and no patient had received T or B cell depleting therapy for induction or rejection within two years before vaccination and thereafter. One patient had received rejection treatment with glucocorticoids within the first two months after transplantation, but more than eleven months before vaccination. Patients had a leukocytosis mainly affecting neutrophils and had significantly less lymphocytes. Among lymphocytes, significantly lower numbers of CD3 T cells and CD19 positive B cells including plasmablasts were observed in patients (Table 1 ).

Spike-specific IgG levels were significantly higher among immunocompetent controls than in transplant recipients both after the first and the second vaccination ( Figure 1A CD4 and CD8 T cell reactivity after polyclonal stimulation was not impaired in patients ( Figure 1C ). Among the four transplant recipients with evidence of infection, three showed a pronounced SARS-CoV-2-specific cellular immunity, which was similar or even higher in magnitude as compared to vaccine responses in immunocompetent infection-naïve individuals ( Figure 1B) . Overall, SARS-CoV-2-specific IgG levels showed a significant correlation with specific CD4 and CD8 T cells after both the first and the second vaccination, with differences among patients and controls ( Figure 1D , white and gray symbols, and Table S1 ).

The percentages of individuals with cellular and humoral immunity above the respective detection limits are summarized in Table 2 .

While 56/70 controls (80.0%) and only 2/38 (5.3%) of transplant recipients had IgG levels above the threshold after the first vaccination, this increased to 100% and 35.3% after booster vaccination (Table 2 ).

In contrast, a larger fraction of patients showed a vaccine-induced F I G U R E 1 T cell and antibody responses in controls and transplant recipients after SARS-CoV-2-specific vaccination. (A) Levels of spikespecific IgG and neutralizing antibodies were determined by ELISA and neutralization assay, respectively, and compared between healthy controls (open symbols) and solid organ transplant recipients (SOT, filled symbols). Levels of SARS-CoV-2-specific (B) and SEB-reactive (C) CD4 and CD8 T cells were flow cytometrically determined after antigen-specific stimulation in vitro followed by intracellular cytokine staining, and compared between groups. In panels A-C, results of four vaccinated transplant recipients with a previously unknown history of asymptomatic SARS- 

As two types of vaccines were administered in our study, we separately analyzed antibody and T cell responses in controls and patients after priming with either vector or mRNA vaccines.

As shown in Figure 2A , induction of SARS-CoV-2-specific IgG and neutralizing antibodies in healthy controls was far more pro- This contrasts with cellular immunity, where both SARS-CoV-2specific CD4 and CD8 T cell levels were significantly higher after vector priming (0.072% of CD4 T cells and 0.106% of CD8 T cells)

as compared to mRNA priming (0.021% of CD4 T cells, p = .009, and 0.007% of CD8 T cells, p < .0001, Figure 2B ). In transplant recipients, this distinction is less discernable, as neutralizing titers of very low inhibitory activity were found exclusively in two patients after mRNA priming, and SARS-CoV-2-specific CD4 T cells only occurred in five patients after vector priming. Apart from this, there were no striking differences between the vaccines in transplant recipients after priming, which may result from a lower general immune reactivity in patients. Likewise, no differences were observed for SEB-reactive T cells ( Figure 2C ). Abbreviations: Ab, antibody; BAU, binding antibody units; IH, percentage of inhibition.

*The patients with evidence of prior infection before vaccination 1 (n = 2) and vaccination 2 (n = 2) are not included in the respective evaluation; one patient refused the second vaccination and one patient was lost to follow-up. # Comparison of none versus any adverse event (Fisher´s exact test), for differences in adverse events between the vaccines see 

In immunocompetent controls, the heterologous and both homologous regimens led to a significant increase in IgG levels and neutralizing activities ( Figure 3A , p < .0001 for all regimens). Likewise, both CD4 and CD8 T cell levels significantly increased after heterologous and homologous mRNA boosting ( Figure 3B ). In contrast, CD4 T cell levels after homologous vector boosting were lower than after priming (p = .0002), and CD8 T cell levels remained unaltered (p = .495, Figure 3B ). In transplant recipients, the heterologous regimen led to a significant induction in IgG levels (p < .0001) and neutralizing activity (p = .004), which was not significant for the homologous regimens. Likewise, CD4 T cell levels significantly increased after heterologous vaccination (p = .0002), and to a lesser extent after homologous mRNA boosting (p = .03, Figure 3B ).

Although CD8 T cell levels also showed a numerical increase after heterologous vaccination, this difference did not reach statistical significance (p = .132).

We also analyzed qualitative differences in specific T cell responses between patients and controls based on cytokine profiling of IFNγ, IL-2, and TNFα in individuals with detectable specific immunity. This analysis was restricted to individuals who had at least 

We have previously shown that induction of SARS-CoV-2-specific immunity after natural infection was associated with an expansion of plasmablasts. 19 To elucidate whether this is also observed after vaccination, vaccine-induced plasmablasts were quantified from whole blood as CD38 positive cells among IgD-CD27+ CD19 positive switched-memory B cells. As shown from 15 healthy controls analyzed before and after the first vaccination, there was a significant increase from 0.88/µl to 1.29/µl (p = .022, data not shown). In the whole group, controls had significantly higher numbers of vaccineinduced plasmablasts compared to transplant recipients after both the first and the second vaccination (p < .0001, Figure 4A ). In line with higher IgG titers in mRNA-vaccinated controls, median numbers of plasmablasts after mRNA priming were slightly higher than after vector priming, although the difference did not reach statistical significance ( Figure 4B ). After secondary vaccination, the three primeboost regimens did not show any difference in neither patients nor controls ( Figure 4B ). However, plasmablast numbers showed a correlation with vaccine-induced IgG titers as well as with SARS-CoV-2specific CD4 T cells after both the first and the second vaccination ( Figure 4C ). In contrast, a correlation with specific CD8 T cells was only found after the second vaccination ( Figure 4C ).

Adverse events in the first week after each vaccination were recorded using a questionnaire. The vaccine was better tolerated among transplant recipients (Table 2) ; the percentage of transplant recipients with neither local nor systemic symptoms was similar after the first and second vaccination (approximately 32%), whereas this was lower among controls (11% after first and 17% after second vaccination). After first vaccination, the vector vaccine caused more systemic adverse events than the mRNA vaccine, which only reached statistical significance in controls (p = .033, Figure 5A ).

After secondary vaccination, mRNA-boosted controls had more systemic adverse events as compared to patients, whereas the majority of controls and patients after homologous vector boosting did not report any adverse events ( Figure 5B ). It is interesting to note, that systemic adverse events were linked to cellular immunity, as individuals with systemic symptoms had higher levels of vaccine-induced SARS-CoV-2-specific CD4 and CD8 T cells as compared to individuals who only had local or no symptoms ( Figure 5C ).

Based on the lack of efficacy trials, knowledge on the adaptive immune response after COVID-19 vaccination in transplant recipients will have the potential to provide guidance for clinical practice. Up to now, data in this patient population are limited to immunity after mRNA vaccination, [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] Our study is novel in that patients on both vector-and mRNA regimens were prospectively included which allowed direct comparison of primary immunogenicity in vaccine naïve individuals independent from variabilities resulting from vaccine-specific differences in the time interval between the first and the second dose. As a further strength of our study, we comprehensively assessed both the humoral immune response with IgG and neutralization capacity, and the cellular immune response that included both CD4 and CD8 T cells and their cytokine profiles. The inclusion of an age-matched control group is considered as an additional asset to provide comparative data on immunogenicity of immunocompetent individuals in a real-world setting. Our definition of responders may be limited by the fact that our threshold for defining a positive T cell response was based on natural variability of T cell immunity after control stimulation as previously established. 4 In the absence of effectiveness data it remains to be determined for both antibodies and T cells, whether the chosen thresholds represent clinically relevant indicators for protection. Our study is further limited by convenience sampling, where assignment of the vaccine regimen was determined by national guidelines, that changed for vector-primed individuals after initiation of our study due to an increased general incidence of cerebral venous thrombosis 28, 29 ;

hence, the study participants were divided into smaller subgroups than initially planned. While we acknowledge the small sample size as a limitation, this offered the possibility to provide first data on the immunogenicity of the heterologous vector-mRNA regimen in transplant recipients.

In conclusion, we show that serology considerably underestimates the immunogenicity of COVID-19 vaccines in both immunocompetent controls and transplant recipients, with an improved ability to identify vaccine responders after combined analysis of humoral and cellular immunity. Despite this advantage, the proportion of responders and the level of immunity among transplant recipients is significantly lower than among controls, which may result in a higher risk of post-vaccination infection. 30 Nevertheless, despite the occurrence of breakthrough infections, there is the first evidence of vaccine-mediated protection from severe disease. [31] [32] [33] This is exemplified by registry data among transplant recipients that indicate a reduction in infection-related mortality from 12% in unvaccinated to 7.7% in recipients of two vaccinations. 32 Until further data on effectiveness and immunological correlates of protection are defined, patients should be advocated for continued adherence to hand hygiene, physical distancing, and use of facemasks. 34 

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine

Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine

Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination

Impact of COVID-19 in solid organ transplant recipients

Beschluss der STIKO zur 3. Aktualisierung der COVID-19-Impfempfehlung und die dazugehörige wissenschaftliche Begründung

Beschluss der STIKO zur 5. Aktualisierung der COVID-19-Impfempfehlung und die dazugehörige wissenschaftliche Begründung

Immunogenicity of a single dose of SARS-CoV-2 messenger RNA vaccine in solid organ transplant recipients

Weak anti-SARS-CoV-2 antibody response after the first injection of an mRNA COVID-19 vaccine in kidney transplant recipients

Kidney transplant recipients rarely show an early antibody response following the first COVID-19 vaccine administration

Reduced humoral response to mRNA SARS-Cov-2 BNT162b2 vaccine in kidney transplant recipients without prior exposure to the virus

Immunogenicity of SARS-CoV-2 BNT162b2 vaccine in solid organ transplant recipients

BNT162b2 vaccination in heart transplant recipients: clinical experience and antibody response

Low immunogenicity to SARS-CoV-2 vaccination among liver transplant recipients

Impaired humoral response in renal transplant recipients to SARS-CoV-2 vaccination with BNT162b2 (Pfizer-BioNTech)

Antibody response to 2-dose SARS-CoV-2 mRNA vaccine series in solid organ transplant recipients

Cellular and humoral immune response after mRNA-1273 SARS-CoV-2 vaccine in liver and heart transplant recipients

Cellular and humoral response after mRNA-1273 SARS-CoV-2 vaccine in kidney transplant recipients

High levels of SARS-CoV-2-specific T cells with restricted functionality in severe courses of COVID-19

Impaired humoral and cellular immunity after SARS-CoV-2 BNT162b2 (tozinameran) prime-boost vaccination in kidney transplant recipients

Three doses of an mRNA Covid-19 vaccine in solid-organ transplant recipients

Antibody response after a third dose of the mRNA-1273 SARS-CoV-2 vaccine in kidney transplant recipients with minimal serologic response to 2 doses

Efficiency of a boost with a third dose of anti-SARS-CoV-2 messenger RNA-based vaccines in solid organ transplant recipients

Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates

Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial

Safety of the first dose of SARS-CoV-2 vaccination in solid organ transplant recipients

Safety and reactogenicity of 2 doses of SARS-CoV-2 vaccination in solid organ transplant recipients

Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination

Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination

COVID-19 infection in solid organ transplant recipients after SARS-CoV-2 vaccination

Risk of breakthrough SARS-CoV-2 infections in adult transplant recipients

Two doses of SARS-CoV-2 vaccines reduce risk of death due to COVID-19 in solid organ transplant recipients: preliminary outcomes from a UK registry linkage analysis

Perspectives on COVID-19 vaccination among kidney and pancreas transplant recipients living in New York City

The future of SARS-CoV-2 vaccines in transplant recipients: to be determined

The authors thank Candida Guckelmus and Rebecca Urschel for excellent technical assistance, and Susanne Brehmer, Inna Vallar, Fabio Lizzi and the team of the Saarland University Transplant center for their valuable support. The authors also thank all participants to this study who contributed to the gain in knowledge from this project. Financial support was given by the State Chancellery of the Saarland.

The authors of this manuscript have conflicts of interest to dis- 

All figures have associated raw data. The data that support the findings of this study are available from the corresponding author upon reasonable request.